Workflow
人民币单位结构性存款DWJCSH25064
icon
Search documents
中源协和细胞基因工程股份有限公司2025年第二次临时股东大会决议公告
● 本次会议是否有否决议案:无 一、会议召开和出席情况 (一)股东大会召开的时间:2025年12月15日 (二)股东大会召开的地点:天津市滨海高新区华苑产业区梅苑路12号公司会议室 证券代码:600645 证券简称:中源协和 公告编号:2025-052 中源协和细胞基因工程股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示: 会议采用现场投票和网络投票相结合的表决方式,符合《公司法》和《公司章程》的有关规定,经公司 半数以上董事推举,本次股东大会由副董事长、总经理WANG HONGQI(王洪琦)先生主持。 (五)公司董事、监事和董事会秘书的出席情况 1、公司在任董事9人,出席6人,董事长龚虹嘉先生、独立董事裴端卿先生和罗明生先生因工作原因未 能出席本次会议; 2、公司在任监事3人,出席3人; 3、董事会秘书(代)李旭先生出席本次会议;部分高管和法务顾问列席本次会议。 二、议案审议情况 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况: ■ (四)表 ...
中源协和细胞基因工程股份有限公司关于使用暂时闲置募集资金进行现金管理的进展公告
Core Viewpoint - The company is utilizing temporarily idle raised funds for cash management to enhance fund efficiency and increase returns for the company and its shareholders [2][3][7]. Summary by Sections Cash Management Overview - The purpose of the investment is to improve fund utilization efficiency without affecting the construction of fundraising projects and normal operations [3]. - The amount of idle raised funds used for cash management is 120 million RMB [2][3]. - The source of funds is temporarily idle raised funds from a previous fundraising effort, which totaled approximately 446.99 million RMB, netting about 444.45 million RMB after expenses [4]. Investment Method - The cash management product purchased is a structured deposit with a principal protection and minimum return feature, ensuring high safety and liquidity [5][6]. - The investment does not alter the intended use of the raised funds and does not harm shareholder interests [5]. Review Procedures - The board of directors and supervisory board approved the cash management proposal on December 18, 2024, with no objections from the independent financial advisor [5][6]. Impact on the Company - The cash management initiative is expected to enhance fund efficiency and profitability, benefiting both the company and its shareholders [7]. - The financial reporting will reflect changes in "trading financial assets," "cash and cash equivalents," "financial expenses," "fair value changes," and "investment income" due to this cash management [7].